|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatic and Extrahepatic Colorectal Metastases: When Resectable, Their Localization Does Not Matter, But Their Total Number Has a Prognostic Effect显示文摘 | Dominique Elias MD PhD Gabriel Liberale MD Déwi Vernerey MSc Marc Pocard MD PhD Michel Ducreux MD PhD Valérie Boige MD David Malka MD PhD Jean-Pierre Pignon MD PhD Philippe Lasser MD | 2005 | Annals of Surgical Oncology2005，，11： | 2 |
| 2 | Hepatic and extrahepatic colorectal metastases: When resectable, their localization does not matter, but their total number has a prognostic effect 显示文摘 | Elias D Liberale G Vernerey D | 2005 | Ann Surg Oncol2005，12，11： | 1 |
| 3 | Hepatic and extrhepaticcolorectai metastases:when resectable,their localization does not matter,but their total number has a prognostic effect显示文摘 | Elias D Liberle O Vernerey D | 2005 | Ann Burg 0neol2005，12，11： | 1 |
| 4 | Complement- binding anti-HLA antibodies and kidney-allograft survival显示文摘 | Loupy A Lefaucheur C Vernerey D | 2013 | N Engl J Med2013，369，13： | 1 |
| 5 | Long term outcomes of transplantation using kidneys from expanded criteria donors:prospective,population based cohort study显示文摘 | Aubert O Kamar N Vernerey D | 2015 | BMJ2015，351，： | 1 |
| 6 | Determi-nanls and Outcomes of Accelerated Arteriosclerosis MajorImpact of Circulating Antibodies显示文摘 | LOUPY A VERNEREY D VIGLIETTI D | 2015 | Circulation research2015，117，5： | 1 |
| 7 | Antibody-mediated vascu- lar rejection of kidney allografts : A population-based study 显示文摘 | Lefaucheur C Loupy A Vernerey D | 2013 | Lan- cet2013，381，： | 1 |
| 8 | Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect 显示文摘 | Elias D Liberale G Vernerey D | 2005 | Ann Surg Oncol2005，12，11： | 1 |
| 9 | Quality of life of patients operated on for low rectal cancer:impact of the type of surgery and patients' characteristics显示文摘 | Sideris L Zenasni F Vernerey D | | 0，，12： | 1 |
| 10 | Antibody-mediated vascular rejection of kidney allografts: a population-based study 显示文摘 | Lefaucheur C Loupy A Vernerey D | 2013 | Lancet2013，381，9863： | 1 |
| 11 | Complement- binding anti-HLA antibodies and kidney-aUograft survival显示文摘 | Loupy A Lefaucheur C Vernerey D | 2013 | N Engl J Med2013，369，13： | 1 |
| 12 | Complement-binding anti-HLA antibodies and kidney-allograft survival 显示文摘 | Loupy A Lefancheur C Vernerey D | 2013 | N Engl J Med2013，369，13： | 1 |
| 13 | Complement-binding anti HLA antibodies and kidney-allograft survival显示文摘 | Loupy A Lefaucheur C Vernerey D | 2013 | N Engl J Med2013，369，13： | 1 |
| 14 | Hepatic and extrahepatic colorectal metastases:when respectable,their localization does not matter,but their total number has a prognostic effect显示文摘 | Elias D Liberale G Vernerey D | 2005 | Ann Surg Oncol2005，12，11： | 1 |
| 15 | Hepatic and extrahepatic olorectal metastases:when respectable,their localization does not matter,but their total number has a prognostic effect显示文摘 | Elias D Liberale G Vernerey D | 2005 | Ann Surg Oncol2005，12，11： | 1 |
| 16 | Hepatic and extrahepatic colorectal metastases:when resectable,their localization does not matter,but their total number has a prognostic effect显示文摘 | Elias D Liberale G Vernerey D | 2005 | Ann Surg Oncol2005，12，11： | 1 |
| 17 | Hepatic and extrahepatic colorec- tal metastases: when respectable, their localization does not matter but their total number has a prognostic effect显示文摘 | Elias D Liberale G Vernerey D | 2005 | Ann Surg Oncol2005，12，11： | 1 |
| 18 | Complement- binding anti-HLA antibodies and kidney-allograft survival显示文摘 | Loupy A Lefaucheur C Vernerey D | 2013 | N Engl J Med2013，369，13： | 1 |
| 19 | FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study显示文摘BACKGROUND FOLFIRINOX regimen is the first-line reference chemotherapy(L1)in advanced pancreatic ductal adenocarcinoma(aPDAC).FOLFOXIRI,a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil,has demonstrated efficacy and feasibility in colorectal cancer.AIM To investigate the potential clinical value of FOLFOXIRI in patients with aPDAC in routine clinical practice.METHODS Analyses were derived from all consecutive aPDAC patients treated in L1 between January 2011 and December 2017 in two French institutions,with either FOLFOXIRI(n=165)or FOLFIRINOX(n=124)regimens.FOLFOXIRI consisted of irinotecan(165 mg/m2),oxaliplatin(85 mg/m2),leucovorin(200 mg/m2)and 5-fluorouracil(3200 mg/m2 as a 48-h continuous infusion)every 2 wk.Ninety-six pairs of patients were selected through propensity score matching,and clinical outcomes of the two treatment regimens were compared.RESULTS Median overall survival was 11.1 mo in the FOLFOXIRI and 11.6 mo in the FOLFIRINOX cohorts,respectively.After propensity score matching,survival rates remained similar between the two regimens in terms of overall survival(hazard ratio=1.22;P=0.219)and progression-free survival(hazard ratio=1.27;P=0.120).The objective response rate was 37.1%in the FOLFOXIRI group vs 47.8%in the FOLFIRINOX group(P=0.187).Grade 3/4 toxicities occurred in 28.7%of patients in the FOLFOXIRI cohort vs 19.5%in the FOLFIRINOX cohort(P=0.079).FOLFOXIRI was associated with a higher incidence of grade 3/4 digestive adverse events.Hematopoietic growth factors were used after each chemotherapy cycle and the low hematological toxicity rates were below 5%with both regimens.CONCLUSION FOLFOXIRI is feasible in L1 in patients with aPDAC but does not confer any therapeutic benefit as compared with FOLFIRINOX.The low hematological toxicity rates strengthened the relevance of primary prophylaxis with hematopoietic growth factors. | Angélique Vienot Hortense Chevalier Clément Bolognini Elisabeta Gherga Elodie Klajer Aurélia Meurisse Marine Jary Stefano Kim Christelle d’Engremont Thierry Nguyen Fabien Calcagno Hamadi Almotlak Francine Fein Meher Nasri Syrine Abdeljaoued Anthony Turpin Christophe Borg Dewi Vernerey | 2020 | World Journal of Gastrointestinal Oncology2020，12，3： | 0 |
| 20 | 未累及阑尾的结肠直肠癌引发的腹膜癌部分切除的术前条件显示文摘Objective -To analyse the causes of non resectability of peritoneal carcinomatosis (PC) of non-appendiceal colorectal carcinomas, discovered only at the time of the laparotomy. Summary background data -The combination of a maximal cytoreductive surgery (resecting tumor deposits > 1 mm in diameter) with intraperitoneal chemohyperthermia results in cure a significant number of patients. Complete resection of the PC is the determining factor of this time-consuming and resource-consuming therapy. Unfortunately, it has not been possible, so far, to safely predict complete resectability before carrying out the laparotomy. Methods -All patients with colorectal PC who had undergone a laparotomy in order to receive this new treatment, but who finally presented a non completely resectable P C were included in our study. Their preoperative parameters were retrospectively studied and compared to matched number of patients who had successfully undergo ne this treatment. Results -29 patients had incomplete resection PC at laparoto my. They were compared with 29 matched patients who underwent a complete resecti on of the PC. The factors predicting non resectability were, in decreasing order of frequency: presence or persistence of an ascitis just before the laparotomy (P = 0.0008), progression of the PC while on neo-adjuvant chemotherapy (P = 0.0 1), abnormal CT-imaging (P = 0.03), and sub-occlusive syndrome (P = 0.05). The se parameters were partially inter-related. Conclusion -The persistence of asc itis and any progression of the disease while on chemotherapy are important pred ictive factors of incomplete resectability of nonappendiceal colorectal PC. | Elias D Benizri E Vernerey D. 陈云茹 | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，0，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员